Barr Laboratories, a subsidiary of Barr Pharmaceuticals Inc., confirmed Tuesday that it is challenging Savient’s patents through its June filing of an abbreviated drug application (ANDA) with the U.S. Food and Drug Administration for the product.

Earlier on Tuesday, Savient lodged a patent infringement lawsuit in the U.S. District Court for the District of New Jersey to block Barr from taking steps toward the...